Three Seasons Wealth LLC boosted its position in shares of Merck & Co., Inc. (NYSE:MRK – Free Report) by 295.4% during the 2nd quarter, Holdings Channel reports. The institutional investor owned 15,046 shares of the company’s stock after acquiring an additional 11,241 shares during the period. Three Seasons Wealth LLC’s holdings in Merck & Co., Inc. were worth $1,933,000 as of its most recent filing with the SEC.
A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Norges Bank purchased a new stake in shares of Merck & Co., Inc. during the 4th quarter worth about $3,997,933,000. Wellington Management Group LLP increased its stake in shares of Merck & Co., Inc. by 14.8% in the 4th quarter. Wellington Management Group LLP now owns 86,435,458 shares of the company’s stock valued at $9,098,196,000 after purchasing an additional 11,156,354 shares in the last quarter. Cardano Risk Management B.V. purchased a new position in shares of Merck & Co., Inc. in the 4th quarter valued at about $1,012,530,000. Price T Rowe Associates Inc. MD raised its holdings in Merck & Co., Inc. by 37.9% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 18,753,390 shares of the company’s stock worth $1,973,983,000 after purchasing an additional 5,152,069 shares during the period. Finally, Marshall Wace LLP raised its holdings in Merck & Co., Inc. by 985.4% in the 4th quarter. Marshall Wace LLP now owns 3,969,469 shares of the company’s stock worth $417,826,000 after purchasing an additional 3,603,769 shares during the period. Hedge funds and other institutional investors own 76.07% of the company’s stock.
Insider Activity
In related news, EVP Jennifer Zachary sold 80,315 shares of the stock in a transaction on Wednesday, August 12th. The stock was sold at an average price of $133.46, for a total value of $10,718,839.90. Following the completion of the transaction, the executive vice president directly owned 45,509 shares of the company’s stock, valued at approximately $6,073,631.14. This represents a 63.83% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Chirfi Guindo sold 10,000 shares of the firm’s stock in a transaction on Thursday, August 13th. The shares were sold at an average price of $135.00, for a total value of $1,350,000.00. Following the completion of the transaction, the executive vice president owned 36,613 shares in the company, valued at $4,942,755. The trade was a 21.45% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold 228,238 shares of company stock valued at $29,977,783 in the last three months. Company insiders own 0.17% of the company’s stock.
Wall Street Analyst Weigh In
Get Our Latest Research Report on Merck & Co., Inc.
Merck & Co., Inc. Trading Down 1.3%
Shares of Merck & Co., Inc. stock opened at $150.37 on Friday. The company has a current ratio of 1.32, a quick ratio of 1.10 and a debt-to-equity ratio of 1.22. Merck & Co., Inc. has a twelve month low of $77.58 and a twelve month high of $156.92. The firm has a market capitalization of $370.99 billion, a PE ratio of 120.30, a P/E/G ratio of 6.63 and a beta of 0.21. The firm’s 50-day moving average price is $134.64 and its 200 day moving average price is $123.52.
Merck & Co., Inc. (NYSE:MRK – Get Free Report) last posted its quarterly earnings data on Tuesday, August 4th. The company reported ($0.13) EPS for the quarter, topping the consensus estimate of ($0.26) by $0.13. Merck & Co., Inc. had a return on equity of 16.73% and a net margin of 4.77%.The company had revenue of $16.61 billion during the quarter, compared to analyst estimates of $16.37 billion. During the same period in the previous year, the business earned $2.13 EPS. Merck & Co., Inc.’s quarterly revenue was up 5.1% on a year-over-year basis. Merck & Co., Inc. has set its FY 2026 guidance at 2.660-2.760 EPS. On average, sell-side analysts predict that Merck & Co., Inc. will post 2.76 EPS for the current fiscal year.
Merck & Co., Inc. Dividend Announcement
The company also recently declared a quarterly dividend, which will be paid on Wednesday, October 7th. Investors of record on Tuesday, September 15th will be given a dividend of $0.85 per share. This represents a $3.40 annualized dividend and a dividend yield of 2.3%. The ex-dividend date is Tuesday, September 15th. Merck & Co., Inc.’s payout ratio is presently 272.00%.
About Merck & Co., Inc.
Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.
Founded in the late 19th century as the U.S.
Featured Articles
- Five stocks we like better than Merck & Co., Inc.
- Revolution Medicines Got Its Breakthrough—What Moves It Next?
- Retail Earnings Just Exposed a Bigger Divide in the U.S. Consumer Economy
- FB Financial’s Southern Expansion and Buybacks Drive Analyst Optimism
- AST SpaceMobile Stock Soared 12%—This Was the Catalyst
Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck & Co., Inc. (NYSE:MRK – Free Report).
Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.
